Comparative fitness analysis of D-cycloserine resistant mutants reveals both fitness-neutral and high-fitness cost genotypes
Authors
Evangelopoulos, DProsser, GA
Rodgers, A
Dagg, BM
Khatri, B
Ho, MM
Gutierrez, MG
Cortes, T
de, Carvalho, LPS
Affiliation
Mycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UKIssue Date
2019
Metadata
Show full item recordAbstract
Drug resistant infections represent one of the most challenging medical problems of our time. D-cycloserine is an antibiotic used for six decades without significant appearance and dissemination of antibiotic resistant strains, making it an ideal model compound to understand what drives resistance evasion. We therefore investigated why Mycobacterium tuberculosis fails to become resistant to D-cycloserine. To address this question, we employed a combination of bacterial genetics, genomics, biochemistry and fitness analysis in vitro, in macrophages and in mice. Altogether, our results suggest that the ultra-low rate of emergence of D-cycloserine resistance mutations is the dominant biological factor delaying the appearance of clinical resistance to this antibiotic. Furthermore, we also identified potential compensatory mechanisms able to minimize the severe fitness costs of primary D-cycloserine resistance conferring mutations.Citation
Evangelopoulos D, Prosser GA, Rodgers A, Dagg BM, Khatri B, Ho MM, et al. Comparative fitness analysis of D-cycloserine resistant mutants reveals both fitness-neutral and high-fitness cost genotypes. Nat Commun. 2019 Sep 13;10(1):4177.Journal
Nature CommunicationsDOI
10.1038/s41467-019-12074-zPubMed ID
31519879Additional Links
https://dx.doi.org/10.1038/s41467-019-12074-zType
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41467-019-12074-z
Scopus Count
Collections
Related articles
- Depressing time: Waiting, melancholia, and the psychoanalytic practice of care.
- Authors: Kirtsoglou E, Simpson B, Salisbury L, Baraitser L
- Issue date: 2020
- Identification of 4-Amino-Thieno[2,3-d]Pyrimidines as QcrB Inhibitors in Mycobacterium tuberculosis.
- Authors: Harrison GA, Mayer Bridwell AE, Singh M, Jayaraman K, Weiss LA, Kinsella RL, Aneke JS, Flentie K, Schene ME, Gaggioli M, Solomon SD, Wildman SA, Meyers MJ, Stallings CL
- Issue date: 2019 Sep 11
- Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
- Authors: de Wet TJ, Warner DF, Mizrahi V
- Issue date: 2019 Aug 20
- "I've Spent My Whole Life Striving to Be Normal": Internalized Stigma and Perceived Impact of Diagnosis in Autistic Adults.
- Authors: Huang Y, Trollor JN, Foley KR, Arnold SRC
- Issue date: 2023 Dec 1
- Using Experience Sampling Methodology to Capture Disclosure Opportunities for Autistic Adults.
- Authors: Love AMA, Edwards C, Cai RY, Gibbs V
- Issue date: 2023 Dec 1